NEW YORK (July 28, 2023)—TB Alliance applauds all efforts to expand access responsibly to lifesaving TB technologies. Stimulating market competition through appropriate non-exclusive licenses helps lower prices and reduce barriers to access while working to prevent drug-resistant strains from proliferating. We encourage all TB product developers to use all appropriate tools at their disposal to ensure lifesaving technologies reach those who need them as quickly as possible.
We are encouraged by reports and public statements regarding an agreement between Johnson & Johnson and the Stop TB Partnership’s Global Drug Facility designed to lower the price of bedaquiline through generic competition in high TB burden countries.